Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Academic Article 2012 uri icon

authors

  • Molina JM
  • Chuck SL
  • Study 145 Team (Gutiérrez Rodero F among others)
  • GUTIERREZ RODERO, FELIX
  • Lamarca A
  • Andrade-Villanueva J
  • Clotet B
  • Clumeck N
  • Liu YP
  • Zhong L
  • Margot N
  • Cheng AK

publication date

  • 2012